IL17C and folliculitis: Folliculitis and acne observed in some healthy male study participants in study 2 suggested that biological activity of unclear nature occurred in the dermal epithelium with MOR106 but, overall, the data from all studies indicated targeted therapy for up to 12 weeks to neutralize IL-17C signaling has no impact on pathology in moderate–severe AD.